Investigation of a measurement-based dosimetry approach to beta particle-emitting radiopharmaceutical therapy nuclides across tissue interfaces.

OBJECTIVE: In this work, we present and evaluate a technique for performing interface measurements of beta particle-emitting radiopharmaceutical therapy agents in solution. APPROACH: Unlaminated EBT3 film was calibrated for absorbed dose to water using a NIST matched x-ray beam. Custom acrylic source phantoms were constructed and placed above interfaces comprised of bone, lung, and water equivalent materials. The film was placed perpendicular to these interfaces and measurements for absorbed dose to water using solutions of 90Y and 177Lu were performed and compared to Monte Carlo absorbed dose to water estimates simulated with EGSnrc. Surface and depth dose profile measurements were also performed. MAIN RESULTS: Surface absorbed dose to water measurements agreed with predicted results within 3.6 % for 177Lu and 2.2 % for 90Y. The agreement between predicted and measured absorbed dose to water was better for 90Y than 177Lu for depth dose and interface profiles. In general, agreement within k = 1 uncertainty bounds was observed for both radionuclides and all interfaces. An exception to this was found for the bone to water interface for 177Lu due to the increased sensitivity of the measurements to imperfections in the material surfaces. SIGNIFICANCE: This work demonstrates the feasibility of using radiochromic film for performing absorbed dose to water measurements on beta-emitting radiopharmaceutical therapy agents across material interfaces.

Thermoluminescent dosimeters (TLD-100) for absorbed dose measurements in alpha-emitting radionuclides.

Early works that used thermoluminescent dosimeters (TLDs) to measure absorbed dose from alpha particles reported relatively high variation (10%) between TLDs, which is undesirable for modern dosimetry applications. This work outlines a method to increase precision for absorbed dose measured using TLDs with alpha-emitting radionuclides by applying an alpha-specific chip factor (CF) that individually characterizes the TLD sensitivity to alpha particles. Variation between TLDs was reduced from 21.8% to 6.7% for the standard TLD chips and 7.9% to 3.3% for the thin TLD chips. It has been demonstrated by this work that TLD-100 can be calibrated to precisely measure the absorbed dose to water from alpha-emitting radionuclides.

Active and passive dosimetry for beta-emitting radiopharmaceutical therapy agents in a custom SPECT/CT compatible phantom.

OBJECTIVE: This work introduces a novel approach to performing active and passive dosimetry for beta-emitting radionuclides in solution using common dosimeters. The measurements are compared to absorbed dose to water (Dw) estimates from Monte Carlo (MC) simulations. We present a method for obtaining absorbed dose to water, measured with dosimeters, from beta-emitting radiopharmaceutical agents using a custom SPECT/CT compatible phantom for validation of Monte Carlo based absorbed dose to water estimates. APPROACH: A cylindrical, acrylic SPECT/CT compatible phantom capable of housing an IBA EFD diode, IBA RAZOR diode, Exradin A20-375 parallel plate ion chamber, unlaminated EBT3 film, and thin TLD100 microcubes was constructed for the purpose of measuring absorbed dose to water from solutions of common beta-emitting radiopharmaceutical therapy agents. The phantom is equipped with removable detector inserts that allow for multiple configurations and is designed to be used for validation of image-based absorbed dose estimates with detector measurements. Two experiments with 131I and one experiment with 177Lu were conducted over extended measurement intervals with starting activities of approximately 150 - 350 MBq. Measurement data was compared to Monte Carlo simulations using the egs_chamber user code in EGSnrc 2019. MAIN RESULTS: Agreement within k = 1 uncertainty between measured and MC predicted Dwwas observed for all dosimeters, except the IBA RAZOR diode and the A20-375 ion chamber during the second 131I experiment. Despite the agreement, the measured values generally lower than predicted values by 5 - 15 %. The uncertainties at k=1 remain large (5 - 30 % depending on the dosimeter) relative to other forms of radiation therapy. SIGNIFICANCE: Despite high uncertainties, the overall agreement between measured and simulated absorbed doses is promising for the use of dosimeter-based RPT measurements in the validation of MC predicted Dw. .

Non-contact scintillator imaging dosimetry for total body irradiation in radiotherapy.

Objective.The goal of this work was to assess the potential use of non-contact scintillator imaging dosimetry for tracking delivery in total body irradiation (TBI).Approach. Studies were conducted to measure the time-gated light signals caused by radiation exposure to scintillators that were placed on tissue. The purpose was to assess efficacy in conditions common for TBI, such as the large source to surface distance (SSD) commonly used, the reduced dose rate, the inclusion of a plexiglass spoiler, angle of incidence and effects of peripheral patient support structures. Dose validation work was performed on phantoms that mimicked human tissue optical properties and body geometry. For this work, 1.5 cm diameter scintillating disks were developed and affixed to phantoms under various conditions. A time-gated camera synchronized to the linac pulses was used for imaging. Scintillation intensity was quantified in post processing and the values verified with simultaneous thermolumiescent dosimeter (TLD) measurements. Mean scintillation values in each region were compared to TLD measurements to produce dose response curves, and scatter effects from the spoiler and patient bed were quantified.Main results.The dose determined by scintillators placed in TBI conditions agreed with TLD dose determinations to within 2.7%, and did so repeatedly within 1.0% standard deviation variance. A linear fit between scintillator signal and TLD dose was achieved with anR2= 0.996 across several body sites. Scatter from the patient bed resulted in a maximum increase of 19% in dose.Significance.This work suggests that non-contact scintillator imaging dosimetry could be used to verify dose in real time to patients undergoing TBI at the prescribed long SSD and low dose rate. It also has shown that patient transport stretchers can significantly influence surface dose by increasing scatter.

Preclinical Models of Anal Cancer Combined-Modality Therapy.

INTRODUCTION: There have been no significant changes in anal cancer treatment options in 4 decades. In this study, we highlight two preclinical models designed to assess anal cancer treatments. MATERIALS AND METHODS: Transgenic K14E6/E7 mice were treated with 7, 12-dimethylbenz(a)anthracene until anal tumors developed. Mice were treated with localized radiation in addition to chemotherapy (combined-modality therapy [CMT]) and compared to no treatment control (NTC). K14E6/E7 mouse anal spheroids with and without Pik3ca mutations were isolated and treated with vehicle, LY3023414 (LY3) (a drug previously shown to be effective in cancer prevention), CMT, or CMT + LY3. RESULTS: In the in vivo model, there was a significant increase in survival in the CMT group compared to the NTC group (P = 0.0392). In the ex vivo model, there was a significant decrease in the mean diameter of CMT and CMT + LY3-treated spheroids compared to vehicle (P ≤ 0.0001). For LY3 alone compared to vehicle, there was a statistically significant decrease in spheroid size in the K14E6/E7 group without mutation (P = 0.0004). CONCLUSIONS: We have provided proof of concept for two preclinical anal cancer treatment models that allow for the future testing of novel therapies for anal cancer.

Integration and dosimetric validation of a dynamic collimation system for pencil beam scanning proton therapy.

Objective.To integrate a Dynamic Collimation System (DCS) into a pencil beam scanning (PBS) proton therapy system and validate its dosimetric impact.Approach.Uncollimated and collimated treatment fields were developed for clinically relevant targets using an in-house treatment plan optimizer and an experimentally validated Monte Carlo model of the DCS and IBA dedicated nozzle (DN) system. The dose reduction induced by the DCS was quantified by calculating the mean dose in 10- and 30-mm two-dimensional rinds surrounding the target. A select number of plans were then used to experimentally validate the mechanical integration of the DCS and beam scanning controller system through measurements with the MatriXX-PT ionization chamber array and EBT3 film. Absolute doses were verified at the central axis at various depths using the IBA MatriXX-PT and PPC05 ionization chamber.Main results.Simulations demonstrated a maximum mean dose reduction of 12% for the 10 mm rind region and 45% for the 30 mm rind region when utilizing the DCS. Excellent agreement was observed between Monte Carlo simulations, EBT3 film, and MatriXX-PT measurements, with gamma pass rates exceeding 94.9% for all tested plans at the 3%/2 mm criterion. Absolute central axis doses showed an average verification difference of 1.4% between Monte Carlo and MatriXX-PT/PPC05 measurements.Significance.We have successfully dosimetrically validated the delivery of dynamically collimated proton therapy for clinically relevant delivery patterns and dose distributions with the DCS. Monte Carlo simulations were employed to assess dose reductions and treatment planning considerations associated with the DCS.

PETRA: A pencil beam trimming algorithm for analytical proton therapy dose calculations with the dynamic collimation system.

BACKGROUND: The Dynamic Collimation System (DCS) has been shown to produce superior treatment plans to uncollimated pencil beam scanning (PBS) proton therapy using an in-house treatment planning system (TPS) designed for research. Clinical implementation of the DCS requires the development and benchmarking of a rigorous dose calculation algorithm that accounts for pencil beam trimming, performs monitor unit calculations to produce deliverable plans at all beam energies, and is ideally implemented with a commercially available TPS. PURPOSE: To present an analytical Pencil bEam TRimming Algorithm (PETRA) for the DCS, with and without its range shifter, implemented in the Astroid TPS (.decimal, Sanford, Florida, USA). MATERIALS: PETRA was derived by generalizing an existing pencil beam dose calculation model to account for the DCS-specific effects of lateral penumbra blurring due to the nickel trimmers in two different planes, integral depth dose variation due to the trimming process, and the presence and absence of the range shifter. Tuning parameters were introduced to enable agreement between PETRA and a measurement-validated Dynamic Collimation Monte Carlo (DCMC) model of the Miami Cancer Institute's IBA Proteus Plus system equipped with the DCS. Trimmer position, spot position, beam energy, and the presence or absence of a range shifter were all used as variables for the characterization of the model. The model was calibrated for pencil beam monitor unit calculations using procedures specified by International Atomic Energy Agency Technical Report Series 398 (IAEA TRS-398). RESULTS: The integral depth dose curves (IDDs) for energies between 70 MeV and 160 MeV among all simulated trimmer combinations, with and without the ranger shifter, agreed between PETRA and DCMC at the 1%/1 mm 1-D gamma criteria for 99.99% of points. For lateral dose profiles, the median 2-D gamma pass rate for all profiles at 1.5%/1.5 mm was 99.99% at the water phantom surface, plateau, and Bragg peak depths without the range shifter and at the surface and Bragg peak depths with the range shifter. The minimum 1.5%/1.5 mm gamma pass rates for the 2-D profiles at the water phantom surface without and with the range shifter were 98.02% and 97.91%, respectively, and, at the Bragg peak, the minimum pass rates were 97.80% and 97.5%, respectively. CONCLUSION: The PETRA model for DCS dose calculations was successfully defined and benchmarked for use in a commercially available TPS.

Simultaneous photon counting and charge integrating for pulse pile-up correction in paralyzable photon counting detectors.

Objective.In photon counting detectors (PCDs), electric pulses induced by two or more x-ray photons can pile up and result in count losses when their temporal separation is less than the detector dead time. The correction of pulse pile-up-induced count loss is particularly difficult for paralyzable PCDs since a given value of recorded counts can correspond to two different values of true photon interactions. In contrast, charge (energy) integrating detectors work by integrating collected electric charge induced by x-rays over time and do not suffer from pile-up losses. This work introduces an inexpensive readout circuit element to the circuits of PCDs to simultaneously collect time-integrated charge to correct pile-up-induced count losses.Approach.Prototype electronics were constructed to collect time-integrated charges simultaneously with photon counts. A splitter was used to feed the electric signal in parallel to both a digital counter and a charge integrator. After recording PCD counts and integrating collected charge, a lookup table can be generated to map raw counts in the total- and high-energy bins and total charge to estimate pile-up-free true counts. Proof-of-concept imaging experiments were performed with a CdTe-based PCD array to test this method.Main results.The proposed electronics successfully recorded photon counts and time-integrated charge simultaneously, and whereas photon counts exhibited paralyzable pulse pile-up, time-integrated charge using the same electric signal as the counts measurement was linear with x-ray flux. With the proposed correction, paralyzable PCD counts became linear with input flux for both total- and high-energy bins. At high flux levels, uncorrected post-log measurements of PMMA objects severely overestimated radiological path lengths for both energy bins. After the proposed correction, the non-monotonic measurements again became linear with flux and accurately represented the true radiological path lengths. No impact on the spatial resolution was observed after the proposed correction in images of a line-pair test pattern.Significance.Time-integrated charge can be used to correct for pulse pile-up in paralyzable PCDs where analytical solutions may be difficult to use, and integrated charge can be collected simultaneously with counts using inexpensive electronics.

IMRT QA result prediction via MLC transmission decomposition.

BACKGROUND: Quality assurance measurement of IMRT/VMAT treatment plans is resource intensive, and other more efficient methods to achieve the same confidence are desirable. PURPOSE: We aimed to analyze treatment plans in the context of the treatment planning systems that created them, in order to predict which ones will fail a standard quality assurance measurement. To do so, we sought to create a tool external to the treatment planning system that could analyze a set of MLC positions and provide information that could be used to calculate various evaluation metrics. METHODS: The tool was created in Python to read in DICOM plan files and determine the beam fluence fraction incident on each of seven different zones, each classified based on the RayStation MLC model. The fractions, termed grid point fractions, were validated by analyzing simple test plans. The average grid point fractions, over all control points for 46 plans were then computed. These values were then compared with gamma analysis pass percentages and median dose differences to determine if any significant correlations existed. RESULTS: Significant correlation was found between the grid point fraction metrics and median dose differences, but not with gamma analysis pass percentages. Correlations were positive or negative, suggesting differing model parameter value sensitivities, as well as potential insight into the treatment planning system dose model. CONCLUSIONS: By decomposing MLC control points into different transmission zones, it is possible to create a metric that predicts whether the analyzed plan will pass a quality assurance measurement from a dose calculation accuracy standpoint. The tool and metrics developed in this work have potential applications in comparing clinical beam models or identifying their weak points. Implementing the tool within a treatment planning system would also provide more potential plan optimization parameters.

Creation of waterproof, TLD probes for dose measurements to validate image-based radiopharmaceutical therapy dosimetry workflow.

Voxel-level dosimetry based on nuclear medicine images offers patient-specific personalization of radiopharmaceutical therapy (RPT) treatments. Clinical evidence is emerging demonstrating improvements in treatment precision in patients when voxel-level dosimetry is used compared to MIRD. Voxel-level dosimetry requires absolute quantification of activity concentrations in the patient, but images from SPECT/CT scanners are not quantitative and require calibration using nuclear medicine phantoms. While phantom studies can validate a scanner's ability to recover activity concentrations, these studies provide only a surrogate for the true metric of interest: absorbed doses. Measurements using thermoluminescent dosimeters (TLDs) are a versatile and accurate method of measuring absorbed dose. In this work, a TLD probe was manufactured that can fit into currently available nuclear medicine phantoms for the measurement of absorbed dose of RPT agents. Next, 748 MBq of I-131 was administered to a 16 ml hollow source sphere placed in a 6.4 L Jaszczak phantom in addition to six TLD probes, each holding 4 TLD-100 1 × 1 × 1 mm TLD-100 (LiF:Mg,Ti) microcubes. The phantom then underwent a SPECT/CT scan in accordance with a standard SPECT/CT imaging protocol for I-131. The SPECT/CT images were then input into a Monte Carlo based RPT dosimetry platform named RAPID and a three dimensional dose distribution in the phantom was estimated. Additionally, a GEANT4 benchmarking scenario (denoted 'idealized') was created using a stylized representation of the phantom. There was good agreement for all six probes, the differences between measurement and RAPID ranged between -5.5% and 0.9%. The difference between the measured and the idealized GEANT4 scenario was calculated and ranged from -4.3% and -20.5%. This work demonstrates good agreement between TLD measurements and RAPID. In addition, it introduces a novel TLD probe that can be easily introduced into clinical nuclear medicine workflows to provide QA of image-based dosimetry for RPT treatments.

Evaluating on-board kVCT- and MVCT-based dose calculation accuracy using a thorax phantom for helical tomotherapy treatments.

Purpose.To evaluate the impact of CT number calibration and imaging parameter selection on dose calculation accuracy relative to the CT planning process in thoracic treatments for on-board helical CT imaging systems used in helical tomotherapy.Methods and Materials.Direct CT number calibrations were performed with appropriate protocols for each imaging system using an electron density phantom. Large volume and SBRT treatment plans were simulated and optimized for planning CT scans of an anthropomorphic thorax phantom and transferred to registered kVCT and MVCT scans of the phantom as appropriate. Relevant DVH metrics and dose-difference maps were used to evaluate and compare dose calculation accuracy relative to the planning CT based on a variation in imaging parameters applied for the on-board systems.Results.For helical kVCT scans of the thorax phantom, median differences in DVH parameters for the large volume treatment plan were less than ±1% with dose to the target volume either over- or underestimated depending on the imaging parameters utilized for CT number calibration and thorax phantom acquisition. For the lung SBRT plan calculated on helical kVCT scans, median dose differences were up to -2.7% with a more noticeable dependence on parameter selection. For MVCT scans, median dose differences for the large volume plan were within +2% with dose to the target overestimated regardless of the imaging protocol.Conclusion.Accurate dose calculations (median errors of <±1%) using a thorax phantom simulating realistic patient geometry and scatter conditions can be achieved with images acquired with a helical kVCT system on a helical tomotherapy unit. This accuracy is considerably improved relative to that achieved with the MV-based approach. In a clinical setting, careful consideration should be made when selecting appropriate kVCT imaging parameters for this process as dose calculation accuracy was observed to vary with both parameter selection and treatment type.

AAPM medical physics practice guideline 13.a: HDR brachytherapy, part A.

The American Association of Physicists in Medicine (AAPM) is a nonprofit professional society whose primary purposes are to advance the science, education, and professional practice of medical physics. The AAPM has more than 8000 members and is the principal organization of medical physicists in the United States. The AAPM will periodically define new practice guidelines for medical physics practice to help advance the science of medical physics and to improve the quality of service to patients throughout the United States. Existing medical physics practice guidelines (MPPGs) will be reviewed for the purpose of revision or renewal, as appropriate, on their fifth anniversary or sooner. Each medical physics practice guideline represents a policy statement by the AAPM, has undergone a thorough consensus process in which it has been subjected to extensive review, and requires the approval of the Professional Council. The medical physics practice guidelines recognize that the safe and effective use of diagnostic and therapeutic radiology requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice guidelines and technical standards by those entities not providing these services is not authorized. The following terms are used in the AAPM practice guidelines: (1) Must and must not: Used to indicate that adherence to the recommendation is considered necessary to conform to this practice guideline. (2) Should and should not: Used to indicate a prudent practice to which exceptions may occasionally be made in appropriate circumstances. Approved by AAPM's Executive Committee April 28, 2022.

Dosimetric delivery validation of dynamically collimated pencil beam scanning proton therapy.

Objective. Pencil beam scanning (PBS) proton therapy target dose conformity can be improved with energy layer-specific collimation. One such collimator is the dynamic collimation system (DCS), which consists of four nickel trimmer blades that intercept the scanning beam as it approaches the lateral extent of the target. While the dosimetric benefits of the DCS have been demonstrated through computational treatment planning studies, there has yet to be experimental verification of these benefits for composite multi-energy layer fields. The objective of this work is to dosimetrically characterize and experimentally validate the delivery of dynamically collimated proton therapy with the DCS equipped to a clinical PBS system.Approach. Optimized single field, uniform dose treatment plans for 3 × 3 × 3 cm3target volumes were generated using Monte Carlo dose calculations with depths ranging from 5 to 15 cm, trimmer-to-surface distances ranging from 5 to 18.15 cm, with and without a 4 cm thick polyethylene range shifter. Treatment plans were then delivered to a water phantom using a prototype DCS and an IBA dedicated nozzle system and measured with a Zebra multilayer ionization chamber, a MatriXX PT ionization chamber array, and Gafchromic™ EBT3 film.Main results. For measurements made within the SOBPs, average 2D gamma pass rates exceeded 98.5% for the MatriXX PT and 96.5% for film at the 2%/2 mm criterion across all measured uncollimated and collimated plans, respectively. For verification of the penumbra width reduction with collimation, film agreed with Monte Carlo with differences within 0.3 mm on average compared to 0.9 mm for the MatriXX PT.Significance. We have experimentally verified the delivery of DCS-collimated fields using a clinical PBS system and commonly available dosimeters and have also identified potential weaknesses for dosimeters subject to steep dose gradients.

On the perturbation effect and LET dependence of beam quality correction factors in carbon ion beams.

BACKGROUND: In a recent study, we reported beam quality correction factors, fQ , in carbon ion beams using Monte Carlo (MC) methods for a cylindrical and a parallel-plate ionization chamber (IC). A non-negligible perturbation effect was observed; however, the magnitude of the perturbation correction due to the specific IC subcomponents was not included. Furthermore, the stopping power data presented in the International Commission on Radiation Units and Measurements (ICRU) report 73 were used, whereas the latest stopping power data have been reported in the ICRU report 90. PURPOSE: The aim of this study was to extend our previous work by computing fQ correction factors using the ICRU 90 stopping power data and by reporting IC-specific perturbation correction factors. Possible energy or linear energy transfer (LET) dependence of the fQ correction factor was investigated by simulating both pristine beams and spread-out Bragg peaks (SOBPs). METHODS: The TOol for PArticle Simulation (TOPAS)/GEANT4 MC code was used in this study. A 30 × 30 × 50 cm3 water phantom was simulated with a uniform 10 × 10 cm2 parallel beam incident on the surface. A Farmer-type cylindrical IC (Exradin A12) and two parallel-plate ICs (Exradin P11 and A11) were simulated in TOPAS using the manufacturer-provided geometrical drawings. The fQ correction factor was calculated in pristine carbon ion beams in the 150-450 MeV/u energy range at 2 cm depth and in the middle of the flat region of four SOBPs. The kQ correction factor was calculated by simulating the fQo correction factor in a 60 Co beam at 5 cm depth. The perturbation correction factors due to the presence of the individual IC subcomponents, such as the displacement effect in the air cavity, collecting electrode, chamber wall, and chamber stem, were calculated at 2 cm depth for monoenergetic beams only. Additionally, the mean dose-averaged and track-averaged LET was calculated at the depths at which the fQ was calculated. RESULTS: The ICRU 90 fQ correction factors were reported. The pdis correction factor was found to be significant for the cylindrical IC with magnitudes up to 1.70%. The individual perturbation corrections for the parallel-plate ICs were <1.0% except for the A11 pcel correction at the lowest energy. The fQ correction for the P11 IC exhibited an energy dependence of >1.00% and displayed differences up to 0.87% between pristine beams and SOBPs. Conversely, the fQ for A11 and A12 displayed a minimal energy dependence of <0.50%. The energy dependence was found to manifest in the LET dependence for the P11 IC. A statistically significant LET dependence was found only for the P11 IC in pristine beams only with a magnitude of <1.10%. CONCLUSIONS: The perturbation and kQ correction factor should be calculated for the specific IC to be used in carbon ion beam reference dosimetry as a function of beam quality.

The Impact of Parameter Selection and Setup Conditions on Image Quality of an On-Board Helical Kilovoltage Computed Tomography System.

Purpose To evaluate the imaging performance of an on-board helical kilovoltage computed tomography (kVCT) system mounted on a helical tomotherapy unit for various imaging parameters and setup conditions. Methods Images of a commonly used computed tomography (CT) image quality phantom were acquired while varying the selection of available parameters (anatomy, mode, body size) as well as phantom positioning and size. Image quality metrics (IQM) including noise, uniformity, contrast, CT number constancy, and spatial resolution were compared for parameter and setup variations.  Results The use of fine mode improved noise and contrast metrics by 20-30% compared to normal mode and by nearly a factor of two compared to the coarse mode for otherwise identical protocols. Uniformity, CT number constancy, and spatial resolution were also improved for fine mode. Thorax and pelvis anatomy protocols improved noise, uniformity, and contrast metrics by 10-20% compared to images acquired with head protocols. No significant differences in CT number constancy or spatial resolution were observed regardless of anatomy choice. Increasing body size (milliampere second (mAs)/rotation) improved each image quality metric. Vertical and lateral phantom shifts of up to ±6 cm degraded noise and contrast metrics by up to 30% relative to the isocenter while also worsening uniformity and CT number constancy. IQM were also degraded substantially with the use of annuli to increase the phantom diameter (32 cm vs. 20 cm). Despite variations in image characteristics among the investigated changes, most metrics were within manufacturer specifications when applicable. Conclusion This work demonstrates the dependence of image quality on parameter selection and setup conditions for a helical kVCT system utilized in image-guided and adaptive helical tomotherapy treatments. While the overall image quality is robust to variations in imaging parameters, care should be taken when selecting parameters as patient size increases or positioning moves from the isocenter to ensure adequate image quality is still achieved.

Performance evaluation of image reconstruction algorithms for a megavoltage computed tomography system on a helical tomotherapy unit.

Objective. To evaluate the impact of image reconstruction algorithm selection, as well as imaging mode and the reconstruction interval, on image quality metrics for megavoltage computed tomography (MVCT) image acquisition for use in image-guided (IGRT) and adaptive radiotherapy (ART) on a next-generation helical tomotherapy system.Approach. A CT image quality phantom was scanned across all available acquisition modes for filtered back projection (FBP) and both iterative reconstruction (IR) algorithms available on the system. Image quality metrics including noise, uniformity, contrast, spatial resolution, and mean CT number were compared. Analysis of DICOM data was performed using ImageJ software and Python code. ANOVA single factor and Tukey's honestly significant difference post-hoc tests were utilized for statistical analysis.Main Results. Application of both IR algorithms noticeably improved noise and image contrast when compared to the FBP algorithm available on all previous-generation helical tomotherapy systems. Use of the FBP algorithm improved image uniformity and spatial resolution in the axial plane, though values for the IR algorithms were well within tolerances recommended for IGRT and/or MVCT-based ART implementation by the American Association of Physicists in Medicine (AAPM). Additionally, longitudinal resolution showed little dependence on the reconstruction algorithm, while a negligible variation in mean CT number was observed regardless of the reconstruction algorithm or acquisition parameters. Statistical analysis confirmed the significance of these results.Significance. An overall improvement in image quality for metrics most important to IGRT and ART-mainly image noise and contrast-was evident in the application of IR when compared to FBP. Furthermore, since other imaging parameters remain identical regardless of the reconstruction algorithm, this improved image quality does not come at the expense of additional patient dose or an increased scan acquisition time for otherwise identical parameters. These improvements are expected to enhance fidelity in IGRT and ART implementation.

Characterization of imaging performance of a novel helical kVCT for use in image-guided and adaptive radiotherapy.

ClearRT helical kVCT imaging for the Radixact helical tomotherapy system recently received FDA approval and is available for clinical use. The system is intended to enhance image fidelity in radiation therapy treatment planning and delivery compared to the prior MV-based onboard imaging approach. The purpose of this work was to characterize the imaging performance of this system and compare this performance with that of clinical systems used in image-guided and/or adaptive radiotherapy (ART) or computed tomography (CT) simulation, including Radixact MVCT, TomoTherapy MVCT, Varian TrueBeam kV OBI CBCT, and the Siemens SOMATOM Definition Edge kVCT. A CT image quality phantom was scanned across clinically relevant acquisition modes for each system to evaluate image quality metrics, including noise, uniformity, contrast, spatial resolution, and CT number linearity. Similar noise levels were observed for ClearRT and Siemens Edge, whereas noise for the other systems was ∼1.5-5 times higher. Uniformity was best for Siemens Edge, whereas most scans for ClearRT exhibited a slight "cupping" or "capping" artifact. The ClearRT and Siemens Edge performed best for contrast metrics, which included low-contrast visibility and contrast-to-noise ratio evaluations. Spatial resolution was best for TrueBeam and Siemens Edge, whereas the three kVCT systems exhibited similar CT number linearity. Overall, these results provide an initial indication that ClearRT image quality is adequate for image guidance in radiotherapy and sufficient for delineating anatomic structures, thus enabling its use for ART. ClearRT also showed significant improvement over MVCT, which was previously the only onboard imaging modality available on Radixact. Although the acquisition of these scans does come at the cost of additional patient dose, reported CTDI values indicate a similar or generally reduced machine output for ClearRT compared to the other systems while maintaining comparable or improved image quality overall.

Using 4D dose accumulation to calculate organ-at-risk dose deviations from motion-synchronized liver and lung tomotherapy treatments.

Tracking systems such as Radixact Synchrony change the planned delivery of radiation during treatment to follow the target. This is typically achieved without considering the location changes of organs at risk (OARs). The goal of this work was to develop a novel 4D dose accumulation framework to quantify OAR dose deviations due to the motion and tracked treatment. The framework obtains deformation information and the target motion pattern from a four-dimensional computed tomography dataset. The helical tomotherapy treatment plan is split into 10 plans and motion correction is applied separately to the jaw pattern and multi-leaf collimator (MLC) sinogram for each phase based on the location of the target in each phase. Deformable image registration (DIR) is calculated from each phase to the references phase using a commercial algorithm, and doses are accumulated according to the DIR. The effect of motion synchronization on OAR dose was analyzed for five lung and five liver subjects by comparing planned versus synchrony-accumulated dose. The motion was compensated by an average of 1.6 cm of jaw sway and by an average of 5.7% of leaf openings modified, indicating that most of the motion compensation was from jaw sway and not MLC changes. OAR dose deviations as large as 19 Gy were observed, and for all 10 cases, dose deviations greater than 7 Gy were observed. Target dose remained relatively constant (D95% within 3 Gy), confirming that motion-synchronization achieved the goal of maintaining target dose. Dose deviations provided by the framework can be leveraged during the treatment planning process by identifying cases where OAR doses may change significantly from their planned values with respect to the critical constraints. The framework is specific to synchronized helical tomotherapy treatments, but the OAR dose deviations apply to any real-time tracking technique that does not consider location changes of OARs.

Technical note: Tracking target/chest relationship changes during motion-synchronized tomotherapy treatments.

BACKGROUND: Radixact Synchrony® is an intrafraction motion tracking system for helical tomotherapy treatments that uses kV radiographs of the target and LEDs on the patient's chest to synchronize the movement of the radiation beam with the respiratory motion of the target. Several works have demonstrated Synchrony's ability to track target motion when the chest and target motions are perfectly correlated. PURPOSE: The purpose of this work was to determine Synchrony's ability to accurately adapt to scenarios with a changing target/chest correlation. METHODS: A custom ion chamber mimicking plug with embedded fiducials was placed inside a Delta4 Phantom+ and used as the tracking object. A separate motion stage was programmed to mimic chest motion. The target and chest surrogate phantom were programmed to move sinusoidally and two types of target/chest relationship changes were introduced: rigid shifts and linear drifts of the target position but not surrogate position. Tracking analysis was performed by comparing programmed phantom motion to log files of the Synchrony-modeled motion. No dosimetry was performed in this work. RESULTS: At the fastest imaging rate of 2 s/img, Synchrony accurately adapted for gradual drifts in the target location (up to 5 mm/min) with minor increases in tracking errors and adapted for an abrupt 5 mm shift after about 30 s (with an auto-pause threshold at 60 s). When the imaging period was longer (> 4 s/img), larger tracking errors (> 5 mm) were observed, and the treatment would be paused. The measured delta (MD) parameter (2D target localization error on the most recent image) was found to be a more responsive indicator of tracking errors than the potential difference (PD) parameter (3D estimator of tracking error based on all images in the model). Lastly, the effect of a recent update to the tracking algorithm was found to improve the ability of Synchrony to track target/chest relationship changes. CONCLUSIONS: This work demonstrated that Synchrony can adapt to gradual changes (drifts) in the target/chest relationship, but it takes a finite amount of time to adapt to abrupt shifts. Ability to adapt to these changes increases with increasing imaging frequency. Larger tracking errors were observed in this work than others have reported in the literature due to the introduction of target/chest correlation changes in this work. Future work needs to be performed investigating what type and magnitude of target/chest miscorrelations occur in patients. Lastly, users should ensure they are using the most recent software (3.0.1 or newer) to improve the ability of Synchrony to track these movements.

The Effect of Mouse Size on Dose from an X-Rad320 Irradiator.

Irradiation protocols for murine experiments often use standardized dose rate estimates for calculating dose delivered, regardless of physical variations between mouse subjects. This work sought to determine the significance of mouse size on absorbed dose. Five mouse-like phantoms of various sizes based on the mouse whole-body (MOBY) model were 3D printed. The phantoms were placed in an X-Rad320 biological irradiator and a standard irradiation protocol was used to deliver dose. Dose was measured using thermoluminescent dosimeter (TLD) microcubes inside each phantom, and the relative readings were used to calculate output factors (OFs), normalized to the phantom of median volume. Additionally, the OF for each mouse was simulated in Monte Carlo N-Particle (MCNP) code. For both the TLD measurements and MCNP simulations, the OF for each mouse was determined by both experiments and calculations to be unity within the relative standard uncertainties (k = 1). This work supports comparing results across various studies using the X-Rad320 irradiator without need for corrections based on mouse size.